In the 72-week STEP UP trial, in adults with obesity along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg significantly reduced body weight 1 * Analysis of all patients regardless of if they stayed on treatment 7 Co-primary end point: Percent change in body weight 1* Co-primary end point: Reduction in body weight of 5% 1 * Proportion of patients achieving 5% weight loss at 72 weeks * Confirmatory secondary end points (week 72) 1 * 10% weight loss: 79.8% Wegovy HD vs 20.3% placebo 15% weight loss: 63.8% Wegovy HD vs 7.5% placebo 20% weight loss: 45.5% Wegovy HD vs 2.8% placebo ~1 in 3 people (31.2%) of patients achieved 7 * vs 0% of patients with placebo If all patients stayed on treatment 7 20.7% mean weight loss with Wegovy HD vs 2.4% (6 lb) placebo at 72 weeks, in an idealized scenario estimating efficacy if patients remained on treatment for the duration of the trial and used no other weight-loss therapies 7 Mean baseline body weight: Wegovy HD=247.8 lb

The pilot program has been a bit of a roller coaster for patients, says Bisher Mustafa, a weight-management specialist at Marshall Health, one of the centers in the PEIA pilot program
Additionally, like GPLC, it also stimulates nitric oxide production
Pricing Implications and Market Dynamics The cost-of-goods advantage of small-molecule manufacturing does not automatically translate into lower retail pricing, as pharmaceutical pricing is determined by factors including development costs, market competition, patent protection, payer negotiations, and value-based pricing frameworks
- For mobility aid use, include devices such as cane, walker, wheelchair, rollator, crutches, prosthesis, or other assistive ambulation aids
Adverse Effects: Mild pain or redness at the injection site, very rare systemic reactions